|
| [September 28, 2005] |
 |
Biophan's Breakthrough Biomedical Solutions to be Spotlighted at 6th World Nano-Economic Congress in Singapore; Company's Unique Nanotechnology-Based Innovations to be Presented to International Investment Community
ROCHESTER, N.Y. --(Business Wire)-- Sept. 28, 2005 -- Biophan Technologies, Inc. (OTCBB: BIPH) (Frankfurt/FSE: BTN), a developer of next-generation medical technology, announced that it will present today its nanotechnology-based solutions for the healthcare industry at a World Nano-Economic Congress presentation at the Suntec Singapore International Convention and Exhibition Center.
The high-profile Congress, which draws participants from the international investor and financial community, will include presentations of the latest and most innovative nanotechnology-based developments across numerous fields and industries.
Biophan will highlight the Company's proprietary nanotechnology-based solutions to make medical devices safe, effective and image-compatible with Magnetic Resonance Imaging (MRI) machines in a half-hour presentation entitled, "Nanotechnology for Medical Devices and Biomaterial Applications," scheduled for 2:05 p.m. local time.
The World Nano-Economic Congress, previously held in such locations as Washington, D.C., London, Munich and Dublin, features world-renowned speakers from academia, industry and government, and draws more than 10,000 participants to a variety of conferences and events. Attendees expected this year include venture capitalists, private equity institutions, scientific thought leaders, entrepreneurs and leading technology innovators - providing presenters with valuable new exposure and global visibility.
Due to various safety and compatibility problems, millions of patients with implanted devices are denied access to MRI systems. Biophan has developed a wide range of novel MRI-enabling technologies for pacemakers, defibrillators, neurostimulators, stents, vena cava filters, catheters, guidewires, drug pumps and other devices.
Recently, Biophan signed a milestone agreement to license some of its proprietary medical device technologies to major medical manufacturer, Boston Scientific (NYSE: BSX - News). The Company is in ongoing discussions with other large medical manufacturers.
About the World Nano-Economic Congress (WNEC)
WNEC events have established themselves as comprehensive meetings that bring together the thought leaders in science, government, and business to discuss the entire value chain of nanotechnology's commercial development. With Nobel Prize winners, former world leaders, high-ranking government officials, and board members of Fortune 100 companies on its speaker faculty, the WNEC has moved the discussion of nanotechnology from a few nanotechnology evangelists and researchers to those who shape policy and economic initiatives. The WNEC is intended to for the entire value chain of those who are commercializing nanotechnology. Cientifica has been organizing the World Nano-Economic Congress since its initial event in Washington, DC, in September 2003 and the following events in London, Munich and Singapore. Cientifica is the world's largest supplier of nanotechnology information, with activities spanning from basic research, through scientific networks to consultancy, business intelligence and investment appraisals.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 41 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol BTN. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
[ Back To SIP Trunking Community's Homepage ]
|
